Related Experiment Video
Updated: Mar 26, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
The Potential of MicroRNAs as Prostate Cancer Biomarkers
Linda Fabris1, Yvonne Ceder2, Arul M Chinnaiyan3
1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Context:
Short noncoding RNAs known as microRNAs (miRNAs) control protein expression through the degradation of RNA or the inhibition of protein translation. The miRNAs influence a wide range of biologic processes and are often deregulated in cancer. This family of small RNAs constitutes potentially valuable markers for the diagnosis, prognosis, and therapeutic choices in prostate cancer (PCa) patients, as well as potential drugs (miRNA mimics) or drug targets (anti-miRNAs) in PCa management.
Objective:
To review the currently available data on miRNAs as biomarkers in PCa and as possible tools for early detection and prognosis.
Evidence Acquisition:
A systematic review was performed searching the PubMed database for articles in English using a combination of the following terms: microRNA, miRNA, cancer, prostate cancer, miRNA profiling, diagnosis, prognosis, therapy response, and predictive marker.
Evidence Synthesis:
We summarize the existing literature regarding the profiling of miRNA in PCa detection, prognosis, and response to therapy. The articles were reviewed with the main goal of finding a common recommendation that could be translated from bench to bedside in future clinical practice.
Conclusions:
The miRNAs are important regulators of biologic processes in PCa progression. A common expression profile characterizing each tumor subtype and stage has still not been identified for PCa, probably due to molecular heterogeneity as well as differences in study design and patient selection. Large-scale studies that should provide additional important information are still missing. Further studies, based on common clinical parameters and guidelines, are necessary to validate the translational potential of miRNAs in PCa clinical management. Such common signatures are promising in the field and emerge as potential biomarkers.
Patient Summary:
The literature shows that microRNAs hold potential as novel biomarkers that could aid prostate cancer management, but additional studies with larger patient cohorts and common guidelines are necessary before clinical implementation.
Insights
MicroRNAs (miRNAs) show promise as biomarkers for prostate cancer (PCa) detection and prognosis. However, more large-scale studies are needed to validate their clinical use in PCa management.
Area of Science:
- Molecular Biology
- Oncology
- Biomarker Discovery
Background:
- MicroRNAs (miRNAs) are short noncoding RNAs regulating protein expression and are implicated in various cancers, including prostate cancer (PCa).
- Deregulation of miRNAs is common in cancer, suggesting their potential as diagnostic, prognostic, and therapeutic indicators in PCa.
- miRNAs can be targeted for therapeutic strategies, such as miRNA mimics or anti-miRNAs, for PCa management.
Purpose of the Study:
- To systematically review current data on the role of miRNAs as biomarkers in PCa.
- To assess the potential of miRNAs for early detection and prognosis in prostate cancer.
- To explore the utility of miRNA profiling in predicting response to therapy and guiding treatment choices.
Main Methods:
- A systematic literature review was conducted using the PubMed database.
- Search terms included "microRNA," "miRNA," "cancer," "prostate cancer," "miRNA profiling," "diagnosis," "prognosis," "therapy response," and "predictive marker."
- Articles were screened for relevance and data pertaining to miRNA in PCa detection, prognosis, and therapy response.
Main Results:
- miRNAs are key regulators of biological processes in PCa progression.
- A definitive miRNA expression profile for PCa subtypes and stages has not yet been established, likely due to molecular heterogeneity and study variations.
- Current literature indicates that miRNAs hold potential as novel biomarkers for PCa management.
Conclusions:
- While miRNAs show promise as biomarkers in prostate cancer, further research is essential.
- Large-scale studies with standardized methodologies and patient selection are needed to overcome current limitations.
- Validation of miRNA signatures based on common clinical parameters is crucial for their translation into clinical practice for PCa management.
More Related Videos
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs